Frontlight ResearchEarly access
TerminatedPhase 4
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
Key facts
- Who runs it
- Sight Sciences, Inc.
- Where
- Maryville and Petaluma, United StatesSee the 2 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 2 people enrolled
- Started
- 21 Aug 2024
- Ended
- 20 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- OMNI Surgical System
- Latanoprost plus adjunctive glaucoma medication
- Record updated
- 29 January 2025
- Why it stopped
- Business decision by the Sponsor
Who can take part
- Age
- 45 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Male or female subjects, 45 years or older
- History of uncomplicated cataract surgery and posterior chamber intraocular lens (IOL) implantation without compromise to the lens capsule, zonular dehiscence/rupture or vitreous prolapse, 6 months or more prior to Baseline Visit (pseudophakic subjects), OR, phakic and no anticipated need for cataract surgery over the study duration
- Under treatment with a topical prostaglandin F2 analog (e.g. latanoprost, travoprost, bimatoprost, tafluprost) either as monotherapy or in combination with one (1) adjunctive medication for a minimum of 6 weeks prior to the Screening visit
- Intraocular pressure (IOP) at the Screening visit of >18 and not exceeding 36 mmHg
- Diagnosed with primary open angle glaucoma (POAG)
Who cannot take part
- Any of the following prior ocular procedures:; Laser trabeculoplasty ≤180 days prior to baseline; Durysta ≤12 months prior to baseline unless failure is documented and topical medication including a prostaglandin analog is in use as per Inclusion criterion # 3; Implanted with iStent (All types), Cypass, Xen, Express, glaucoma draining device/valve, or Hydrus Device; or; Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, endoscopic cyclophotocoagulation (ECP), Cyclophotocoagulation or CPC (G probe); Retinal laser procedure ≤3 months prior to baseline
- Concurrent IOP-lowering procedure other than the study procedure (OSS) (e.g. ECP, CPC,etc.)
- Forms of glaucoma other than POAG including but not limited to: Pigmentary, pseudoexfoliative, acute angle closure, normal tension, pre-perimetric, traumatic, congenital, malignant, uveitic, neovascular or severe glaucoma as documented in subject's medical record
- Women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study
Where in United States
- University Eye SpecialistsMaryville, United States
- North Bay Eye AssociatesPetaluma, United States
About the trial
What the trial wants to find out
A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
The 2 groups in the trial
- Surgical (OMNI Surgical System (OSS))Existing treatment, for comparison
Canaloplasty followed by Trabeculotomy using the OMNI Surgical System.
Treatment: OMNI Surgical System
- Standard Medical Care (SMC)Existing treatment, for comparison
Standard Medical Care with Latanoprost and one or two adjunctive glaucoma medications at the discretion of the Principal Investigator
Treatment: Latanoprost plus adjunctive glaucoma medication
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Clinical Trial of ab Interno Canaloplasty and Trabeculotomy With the OMNI Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients With Primary Open Angle Glaucoma
- Record updated
- 29 January 2025